Notice NOT-OD-19-024 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-18-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) requests Exploratory Grant (P20) applications for the planning and initiation of collaborative activities to advance Parkinson's Disease (PD) research. The goal of this FOA is to convene new transdisciplinary research consortia and formalize the multi-institutional organizational and investigational structure necessary to resolve an essential challenge in Parkinson's disease (PD) through a subsequent NINDS Udall Center without Walls (CWOW) approach. The most compelling applications will: (i) identify a fundamental PD research priority; (ii) build an exemplary research consortium; (iii) gather supportive preliminary data; and (iv) demonstrate exceptional potential to pursue a targeted strategy to remove a critical impediment blocking advancement of the understanding and treatment of PD. The stated challenge and related research feasibility projects will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the central PD research challenge. To foster the development of innovative research collaborations, this FOA will provide support for new research consortia only; continuation of established projects and teams will not be supported. Proposed consortia must include the optimal combination of specialized expertise required to resolve the stated challenge using a goal-driven approach. The Program Director/Principal Investigator (PD/PI) must be eminently qualified to provide visionary scientific leadership and effective oversight of consortium administrative activities. Participating investigators should be recognized as world-class experts in their fields. Teams must be anchored by at least one PD researcher. To maximize potential for new insights and incorporation of cutting-edge approaches, consortia will actively integrate at least one investigator with primary expertise in another, complementary research area.

Funding Opportunity RFA-NS-18-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinsons Disease Research program. The overarching goal of the specialized Udall Centers program is to establish a network of Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinsons disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Udall Centers also serve as local resources by organizing research career enhancement activities for Center investigators and periodic outreach to the PD patient/advocacy community. Applicants are expected to identify and address an overall research theme that defines a critical challenge in PD research. The stated theme, proposed research projects, and associated cores will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the identified PD research challenge. Requirements include 1) a minimum of three research projects; 2) research cores that are each essential to accomplish the aims of at least two proposed research projects, plus an Administrative Core; 3) a mission statement and plan for career enhancement of Center trainees and investigators; and 4) a plan for effective outreach, including dissemination of Udall Center research results, to the local patient and advocacy community. The NINDS Udall Centers program prioritizes innovative and integrative research with significant potential for discovery. A considerable degree of synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. The Udall Center Director (PD/PI) must be an established leader in scientific research with visionary leadership skills and proven expertise

Notice NOT-HD-18-022 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-19-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications for the development and commercialization of standardized in vitro assays of resilience at the cellular level.

Funding Opportunity RFA-AG-19-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) applications for the development and commercialization of standardized in vitro assays of resilience at the cellular level.

Notice NOT-MH-18-058 from the NIH Guide for Grants and Contracts

Notice NOT-MD-18-019 from the NIH Guide for Grants and Contracts

Notice NOT-HG-19-008 from the NIH Guide for Grants and Contracts

Notice NOT-HG-19-009 from the NIH Guide for Grants and Contracts

Notice NOT-HG-19-007 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-19-120 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to develop and validate new screening methods for autism spectrum disorders (ASD) that can be used in infancy (0-12 months of age). This FOA uses the R01 grant mechanism, while RFA-MH-19-121 uses the R21 grant mechanism. Pilot or exploratory projects with minimal preliminary data, or those proposing early-stage feasibility testing, may be most appropriate for the R21 mechanism. Applicants with strong preliminary data proposing validation, refinement or final stages of testing of existing tools or methods may wish to use this FOA (R01 mechanism).

Funding Opportunity RFA-MH-19-121 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that would develop and validate new screening methods for autism spectrum disorders (ASD) that can be used in infancy (0-12 months of age). This FOA uses the R21 grant mechanism, while RFA- MH-19-120 uses the R01 grant mechanism. Applicants with strong preliminary data proposing validation, refinement or final stages of testing of existing tools or methods may wish to use the R01 mechanism. Pilot or exploratory projects with minimal preliminary data, or those proposing early-stage feasibility testing, may be most appropriate for this FOA (R21 mechanism).

Funding Opportunity PAR-19-038 from the NIH Guide for Grants and Contracts. This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy.

Notice NOT-GM-18-047 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-036 from the NIH Guide for Grants and Contracts. The goal of the Medical Scientist Training Program (MSTP) is to develop a diverse pool of highly trained physician-scientist leaders available to meet the needs of the Nations biomedical research agenda. Specifically, this funding opportunity announcement (FOA) provides support to eligible domestic institutions to develop and implement effective, evidence-based approaches to integrated dual-degree training leading to the award of both professional medical doctorate degrees and research doctorate degrees (Ph.D. or equivalent). With the dual qualification of rigorous scientific research and clinical practice, graduates will be equipped with the skills to develop research programs that accelerate the translation of research advances to the understanding, detection, treatment and prevention of human disease, and to lead the advancement of biomedical research. Areas of particular importance to NIGMS are the iterative optimization of MSTP training efficacy and efficiency, fostering the persistence of MSTP alumni in research careers, and enhancing the diversity of the physician-scientist workforce. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation.

Funding Opportunity PAR-19-037 from the NIH Guide for Grants and Contracts. The goal of the Initiative for Maximizing Student Development (IMSD) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. The long-term goal of the program is to enhance the diversity of biomedical research scientists in the Nations workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-intensive institutions (i.e., those with a 3-year average of NIH Research Project Grant funding equal to or above $7.5 million total costs).

Funding Opportunity RFA-HD-19-022 from the NIH Guide for Grants and Contracts. [Concept listed as CONCEPT-19-000.] The NICHD invites applications from investigators to participate in a multi-site program designed to conduct clinical trials to investigate problems in reproductive medicine, female and male infertility, and gynecologic and male reproductive system diseases and disorders that impact fertility. This funding opportunity announcement (FOA) is intended to support multi-site clinical research consortia devoted to evaluating safety and efficacy of new medications, treatments and technologies addressing questions in infertility. The objective of this program is to advance scientific research that facilitates diagnostic and therapeutic solutions to infertility by using common protocols in large scale human trials to obtain answers more rapidly than individual sites acting alone. This program benefits the public: infertile couples, individuals with reproductive diseases and disorders, and their health care providers. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating sites share a specific protocol across the sites and are organized to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principle Investigator (PD/PI) and each consortium includes a mechanism for coordination, implementation and monitoring of the protocol across sites, quality control, database management, statistical analysis, and reporting.

Notice NOT-TW-18-006 from the NIH Guide for Grants and Contracts

Notice NOT-DK-19-003 from the NIH Guide for Grants and Contracts